| abstract |
Substituted thienobenzodiazepinones of the general formula I <IMAGE> in which R¹ represents a hydrogen atom or an alkyl radical having 1 to 4 carbon atoms, R² represents a halogen atom or has one of the meanings of R¹, R³ represents a halogen atom or the group -N (R²) R <5> and R 4 is an alkyl radical with 1 to 4 carbon atoms or an alkenyl radical with 3 to 5 carbon atoms, R 5 has one of the meanings of R 4 or the group - (CH2) mN (R 5) R <7> or R <4> and R <5> together, including the nitrogen atom to which they are attached, a morpholino group, a pyrrolidino group, a piperidino group, a hexahydroazepin-1-yl group, one optionally in the 4-position a piperazin-1-yl group substituted by a methyl or ethyl group or a benzyl group, a 2,4-dimethylpiperazin-1-yl group or a hexahydro-1H-1 substituted in the 4-position by a methyl or ethyl group, 4-diazepin-1-yl group and R 6 is an alkyl group with 1 up to 4 carbon atoms, R 7 is an alkyl group with 1 to 4 carbon atoms, A is a straight-chain or branched alkylene group with 1 to 5 carbon atoms and m 2 or 3, and their acid addition salts are new compounds. They either have a gastric and intestinal protective effect and are suitable for the treatment of diseases which are based on diseases of the stomach or intestine or are intermediate products. Processes for producing the new pharmacologically active compounds and the intermediate products are specified. |